CA2414500A1 - Association de medicaments agoniste et aversif - Google Patents

Association de medicaments agoniste et aversif Download PDF

Info

Publication number
CA2414500A1
CA2414500A1 CA002414500A CA2414500A CA2414500A1 CA 2414500 A1 CA2414500 A1 CA 2414500A1 CA 002414500 A CA002414500 A CA 002414500A CA 2414500 A CA2414500 A CA 2414500A CA 2414500 A1 CA2414500 A1 CA 2414500A1
Authority
CA
Canada
Prior art keywords
pharmaceutical
combination medicine
alcohol
chosen
benzodiazepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002414500A
Other languages
English (en)
Inventor
Willem Wassenaar
Christopher S. Doyle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purepharm Inc
Original Assignee
Purepharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purepharm Inc filed Critical Purepharm Inc
Priority to CA002414500A priority Critical patent/CA2414500A1/fr
Priority to AU2003303015A priority patent/AU2003303015A1/en
Priority to PCT/CA2003/000990 priority patent/WO2004054570A1/fr
Publication of CA2414500A1 publication Critical patent/CA2414500A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002414500A 2002-12-17 2002-12-17 Association de medicaments agoniste et aversif Abandoned CA2414500A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002414500A CA2414500A1 (fr) 2002-12-17 2002-12-17 Association de medicaments agoniste et aversif
AU2003303015A AU2003303015A1 (en) 2002-12-17 2003-06-25 Combinations of medicaments comprising an alcohol deterrent for treating alcohol dependence or alcohol abuse
PCT/CA2003/000990 WO2004054570A1 (fr) 2002-12-17 2003-06-25 Combinaisons de medicaments comprenant un agent de dissuasion contre l'alcool destinees a traiter la dependance a l'alcool ou l'abus d'alcool

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002414500A CA2414500A1 (fr) 2002-12-17 2002-12-17 Association de medicaments agoniste et aversif

Publications (1)

Publication Number Publication Date
CA2414500A1 true CA2414500A1 (fr) 2004-06-17

Family

ID=32514058

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002414500A Abandoned CA2414500A1 (fr) 2002-12-17 2002-12-17 Association de medicaments agoniste et aversif

Country Status (3)

Country Link
AU (1) AU2003303015A1 (fr)
CA (1) CA2414500A1 (fr)
WO (1) WO2004054570A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019147606A1 (fr) * 2018-01-26 2019-08-01 Presti Michael Traitements combinés pour la crise des opioïdes

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096201A1 (fr) 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions influant sur la perte de poids
EP2135603B1 (fr) 2005-11-22 2013-01-02 Orexigen Therapeutics, Inc. Compositions et procédés pour augmenter la sensibilité à l'insuline
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP2073813A2 (fr) * 2006-10-10 2009-07-01 The University of Chicago Composition et procédé permettant de traiter l'alcoolisme et les addictions à d'autres substances
KR20180066272A (ko) 2006-11-09 2018-06-18 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
US8486448B2 (en) 2007-12-17 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
JP5667575B2 (ja) 2008-12-16 2015-02-12 パラディン ラブス インコーポレーテッド 誤用を防止する放出制御製剤
RU2616496C2 (ru) 2010-01-11 2017-04-17 Ориксиджен Терапьютикс, Инк. Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты)
EP2611440B1 (fr) * 2010-09-01 2017-02-01 Tonix Pharmaceuticals, Inc. Traitement contre la cocaïnomanie
WO2013184837A1 (fr) 2012-06-06 2013-12-12 Orexigen Therapeutics, Inc. Méthodes de traitement de la surcharge pondérale et de l'obésité
EP2705843A1 (fr) * 2012-09-05 2014-03-12 Pharnext Approches thérapeutiques pour le traitement de l'épilepsie et de troubles associés par réduction de l'épileptogenèse
CN110420190B (zh) * 2019-08-29 2021-07-09 湖南洞庭药业股份有限公司 氯硝西泮片及其制备方法
CN111420062A (zh) * 2020-04-29 2020-07-17 漳州卫生职业学院 一种用于苯二氮卓类药物的协同增效剂
WO2022016097A1 (fr) * 2020-07-16 2022-01-20 Musc Foundation For Research Development Inhibition de g9a pour diminuer l'escalade, induite par le stress et induite par la dépendance, de la consommation d'alcool
US20220117916A1 (en) * 2020-10-19 2022-04-21 SafeRx Pharmaceuticals, LLC Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873076A (en) * 1988-04-29 1989-10-10 Baker Cummins Pharmaceuticals, Inc. Method of safely providing anesthesia or conscious sedation
WO1992005787A1 (fr) * 1990-10-01 1992-04-16 Radecki Thomas E Therapie par medicaments pour alcooliques
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019147606A1 (fr) * 2018-01-26 2019-08-01 Presti Michael Traitements combinés pour la crise des opioïdes
US10478408B2 (en) 2018-01-26 2019-11-19 Michael Presti Combination treatments for opioid crisis
US10881625B2 (en) 2018-01-26 2021-01-05 Michael Presti Combination treatments for opioid crisis
US11786490B2 (en) 2018-01-26 2023-10-17 Michael Presti Combination treatments for opioid crisis

Also Published As

Publication number Publication date
AU2003303015A1 (en) 2004-07-09
WO2004054570A1 (fr) 2004-07-01

Similar Documents

Publication Publication Date Title
RU2281771C2 (ru) Использование декстрометорфана и ингибитора оксидазы для отучения пациентов от наркотиков и антидепрессантов
CA2414500A1 (fr) Association de medicaments agoniste et aversif
Griffiths et al. Benzodiazepine self-administration in humans and laboratory animals–implications for problems of long-term use and abuse
US8012958B2 (en) Methods for treating anxiety related disorders
US8791138B2 (en) Compositions and methods for alleviating depression or improving cognition
AU2005223691B2 (en) Methods for treating alcoholism
Simons H1-receptor antagonists: safety issues
PT1691811E (pt) Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
MXPA02001568A (es) Ciclobenzaprina para tratar trastornos de ansiedad generalizada y composiciones de la misma.
Nikolaus et al. Pharmacological treatments for persistent non-malignant pain in older persons
Halpern Analgesic drugs in the management of pain
TWI313598B (en) Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
US9181201B2 (en) Method of treatment of anxiety disorder comorbid with depression disorder
US6344487B1 (en) Treatment of insomnia
US6395727B1 (en) Method of treating Bulimia Nervosa and related eating disorders by administration of atypical antipsychotic medications
CN101272683A (zh) 治疗与焦虑有关疾病的方法
BR112019010077A2 (pt) terapias para o tratamento de condições hipocalêmicas e de ineficácia da lidocaína
CN114585354A (zh) 用芬氟拉明治疗癫痫患者的方法
Tablets Prescribing information
ULC Anxiolytic-Antipanic
Tablets Full Prescribing Information
Ciraulo et al. The pharmacology of nonalcohol sedative hypnotics
Dickerson Palliative care pocket consultant
US20060148783A1 (en) Method and medicine for treating gastrointestinal disorder including fecal incontinence
Like Luvox may cause profuse sweating

Legal Events

Date Code Title Description
FZDE Dead